What is the recommended dosing of cefepime for patients with Impaired renal function (IRF) undergoing Hemodialysis (HD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefepime Dosing in Hemodialysis Patients

For patients on hemodialysis, cefepime should be administered at a dose of 1 g on day 1, followed by 500 mg every 24 hours after each hemodialysis session. 1

Pharmacokinetics of Cefepime in Hemodialysis

Cefepime is primarily eliminated by the kidneys, making dosage adjustment essential in patients with end-stage renal disease (ESRD) on hemodialysis. Key pharmacokinetic considerations include:

  • Approximately 68% of cefepime is removed during a 3-hour hemodialysis session 1
  • The interdialytic half-life is significantly prolonged (22 hours) compared to patients with normal renal function 2
  • High-flux dialysis membranes can remove up to 72% of cefepime during a single session 2

Recommended Dosing Strategy

The FDA-approved dosing regimen for cefepime in hemodialysis patients is:

  • Initial dose: 1 g on day 1
  • Maintenance dose: 500 mg every 24 hours
  • For febrile neutropenia: 1 g every 24 hours 1

Administration timing:

  • Administer after completion of hemodialysis on dialysis days 1
  • This timing prevents premature drug removal during dialysis and maintains therapeutic levels 3

Special Considerations

Residual Renal Function

  • Patients with residual renal function may have lower pre-dialysis cefepime concentrations compared to anuric patients (9.25 mg/L vs. 15.6 mg/L) 4
  • This may necessitate higher doses in patients with preserved diuresis when treating less susceptible pathogens 4

Infection Severity and Pathogen Susceptibility

For severe infections or less susceptible pathogens (e.g., Pseudomonas aeruginosa):

  • Higher doses may be considered (1-2 g post-dialysis) 4
  • The American Thoracic Society recommends adjusting frequency rather than dose to maintain efficacy while preventing toxicity 3

Monitoring Recommendations

  • Monitor for signs of neurotoxicity, which can manifest as seizures, confusion, or encephalopathy 5
  • Elderly patients may be more susceptible to cefepime-induced neurotoxicity, even at adjusted doses 5
  • Therapeutic drug monitoring may be beneficial in patients showing signs of toxicity 3

Alternative Dosing Approach Based on Dialysis Schedule

Research suggests an alternative dosing strategy based on the interdialytic interval:

  • For 48-hour intervals: 1 g post-dialysis
  • For 72-hour intervals: 1.5 g post-dialysis 4

For less susceptible pathogens:

  • For 48-hour intervals: 1.5 g post-dialysis
  • For 72-hour intervals: 2 g post-dialysis 4

Potential Adverse Effects

  • Neurotoxicity is a significant concern, particularly in elderly patients 5
  • Symptoms may include seizures, encephalopathy, and altered mental status
  • Risk factors include advanced age, higher doses, and uremic encephalopathy 5
  • If neurotoxicity is suspected, discontinue cefepime and consider additional dialysis to enhance drug clearance 5

In summary, cefepime dosing in hemodialysis patients requires careful consideration of the dialysis schedule, infection severity, and patient factors. The FDA-approved regimen of 1 g on day 1 followed by 500 mg every 24 hours administered post-dialysis provides adequate coverage for most infections while minimizing toxicity risk.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.